Vanguard Personalized Indexing Management
QNCX icon

Vanguard Personalized Indexing Management’s Quince Therapeutics QNCX Stock Holding History

Vanguard Personalized Indexing Management’s Portfolio QNCX Stock Details QNCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-663
Closed -$13.5K – 2319
2026
Q1 		$13.5K Buy
+663
New +$133K ﹤0.01% 2140

Other funds holding QNCX

Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
SC
Shay Capital New York $1.56B AUM 46.17% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Vanguard Personalized Indexing Management's QNCX Position: Q2 2026 in Review

Vanguard Personalized Indexing Management sold out of Quince Therapeutics (QNCX) in Q2 2026, closing a stake of 663 shares — an estimated $13.5K sold.

Vanguard Personalized Indexing Management first reported a position in QNCX in Q1 2026 and held it in 1 quarter. The position peaked at $13.5K in Q1 2026. 27 funds tracked by Wall St. Rank hold QNCX as of Q2 2026.

  • Vanguard Personalized Indexing Management reported no remaining Quince Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Vanguard Personalized Indexing Management sold 663 Quince Therapeutics shares in Q2 2026, an estimated $13.5K.
  • Vanguard Personalized Indexing Management first reported a position in Quince Therapeutics in Q1 2026 and held it in 1 quarter.
  • Vanguard Personalized Indexing Management's Quince Therapeutics position peaked at $13.5K in Q1 2026.
  • 27 funds tracked by Wall St. Rank held Quince Therapeutics as of Q2 2026.

Based on Vanguard Personalized Indexing Management's 13F filing for Q2 2026, filed 11 Aug 2026.